Table 4

Response to first TNF╬▒ inhibitors, percentage achieving response by ACR response criteria or decrease in disease activity by one DAS28-CRP or DAPSA28 category, along with availability of response calculations

Improvement in clinical scores
n (%)
6 monthsP value18 monthsP value
InclExclInclExcl
ACR response available26522649
ACR20 achieved20 (77%)31 (60%)0.2518 (69%)29 (59%)0.55
ACR50 achieved15 (58%)21 (40%)0.2317 (65%)18 (37%)0.034
ACR70 achieved7 (27%)12 (23%)0.9313 (50%)14 (28%)0.11
DAS28 available26512651
Response by DAS28-CRP20 (77%)36 (71%)0.7521 (81%)34 (67%)0.30
DAPSA28 available23462449
Response by DAPSA2819 (83%)32 (70%)0.3818 (75%)35 (71%)0.97
  • ACR20/50/70, American College of Rheumatology response criteria, improvement by 20%/50%/70%; DAPSA28, Disease Activity Score in Psoriatic Arthritis for 28 joints; DAS28, Disease Activity Score for 28 joints; DAS28-CRP, Disease Activity Score 28-joint count C reactive protein.